Arlington Capital Partners Announces Acquisitions of Thortex and Millennium Surgical by Avalign Technologies
July 25, 2017
WASHINGTON–(BUSINESS WIRE)–Avalign Technologies (“Avalign”), a portfolio company of Arlington Capital Partners (“Arlington Capital”), has completed the acquisitions of Thortex and Millennium Surgical (“Millennium”).
Thortex is a leading provider of proprietary porous coatings and metal injection molding as well precision manufacturing solutions to the medical device market. Thortex is one of the only companies in the world able to provide porous coating solutions for titanium and cobalt-chrome orthopedic implants. In addition, Thortex provides a full suite of manufacturing and engineering technologies including metal injection molding, CNC machining, finishing and assembly to medical device OEMs.
Millennium is a provider of specialty surgical instruments focused on delivering difficult-to-find instruments utilizing innovative, e-cataloging, web-based marketing tools, and technical sales support. Millennium offers more than 17,000 branded SKUs across a variety of clinical areas including neurosurgery, ophthalmics and orthopedics to a diverse array of hospital and ambulatory surgical center customers.
Matt Altman, a Managing Partner at Arlington Capital said, “The incorporation of Thortex and Millennium into the Avalign platform adds new and proprietary capabilities which enhance Avalign’s strategic position in the marketplace. The increased scale and breadth of services and technologies provided by these acquisitions will accrue to the benefit of Avalign’s customers and bolster Avalign’s already impressive growth.”
“Thortex and Millennium nicely complement and expand the manufacturing technologies and services that Avalign offers and provide us with the ability to continue gaining share with our customers,” said Forrest Whittaker, CEO of Avalign Technologies. “We are excited to welcome the Thortex and Millennium teams to the Avalign family, and thankful for Arlington’s support in consummating these highly strategic acquisitions.”
Malcolm Little, a Principal at Arlington Capital, added: “The proprietary technologies developed by both Thortex and Millennium represent truly unique offerings in the market. We are pleased to complete these acquisitions and continue to pursue additional opportunities to strategically scale our business.”
About Avalign Technologies
Avalign Technologies, Inc. (“Avalign”) is a leading provider of proprietary coatings and full-service precision manufacturer of implants, specialty instrumentation, cutting instruments, and delivery systems to the orthopedic medical device and specialty surgical markets. Avalign offers its OEM partners a broad portfolio of manufacturing technologies and coating solutions as well as extensive engineering design, development, and project management capabilities from concept to launch. Avalign has an established reputation for consistent and sophisticated quality systems, flexible capacity capabilities, innovative proprietary manufacturing technologies, unmatched product offering, and superior customer service.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion of committed capital via four investment funds, including Arlington’s fourth and most recent $700 million fund. Arlington is focused on middle market investment opportunities in growth industries including: healthcare, aerospace/defense, government services and technology and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field. www.arlingtoncap.com
Arlington Capital Partners
Matt Altman or Malcolm Little
5425 Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815